Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural history of t(11;14) multiple myeloma.
Lakshman A, Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Lakshman A, et al. Among authors: fonder al. Leukemia. 2018 Jan;32(1):131-138. doi: 10.1038/leu.2017.204. Epub 2017 Jun 27. Leukemia. 2018. PMID: 28655925
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.
Vaxman I, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Kapoor P, Grogan M, Go R, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Gertz MA, Dispenzieri A. Vaxman I, et al. Leukemia. 2021 Dec;35(12):3604-3607. doi: 10.1038/s41375-021-01297-z. Epub 2021 May 21. Leukemia. 2021. PMID: 34021252 Free PMC article. No abstract available.
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.
Vaxman I, Abeykoon J, Dispenzieri A, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Reeder C, Sher T, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Go R, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Kristen M, Kapoor P, Gertz MA. Vaxman I, et al. Blood Cancer J. 2021 Dec 7;11(12):196. doi: 10.1038/s41408-021-00592-3. Blood Cancer J. 2021. PMID: 34876555 Free PMC article.
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.
Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR, Leung N, Go RS, Dingli D, Kapoor P, Lin Y, Hwa YL, Fonder AL, Hobbs MA, Zeldenrust SR, Lust JA, Gonsalves WI, Russell SJ, Kumar SK. Tandon N, et al. Among authors: fonder al. Blood Cancer J. 2017 Feb 17;7(2):e528. doi: 10.1038/bcj.2017.13. Blood Cancer J. 2017. PMID: 28211889 Free PMC article.
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK. Sidana S, et al. Among authors: fonder al. Leukemia. 2018 Mar;32(3):729-735. doi: 10.1038/leu.2017.286. Epub 2017 Sep 18. Leukemia. 2018. PMID: 28919633
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis.
Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, Kumar SK, Leung N, Muchtar E, Buadi FK, Warsame R, Kyle RA, Lacy MQ, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hayman SR, Hwa YL, Fonder A, Hobbs M, Jevremovic D, Lust JA, Zeldenrust S, Russell SJ, Rajkumar SV, Gertz MA, Murray D. Dispenzieri A, et al. Blood Cancer J. 2020 Feb 25;10(2):20. doi: 10.1038/s41408-020-0291-8. Blood Cancer J. 2020. PMID: 32098948 Free PMC article.
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Among authors: fonder al. Blood Cancer J. 2023 Dec 11;13(1):183. doi: 10.1038/s41408-023-00957-w. Blood Cancer J. 2023. PMID: 38072941 Free PMC article. No abstract available.
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Among authors: fonder al. Blood Adv. 2023 Aug 22;7(16):4371-4380. doi: 10.1182/bloodadvances.2023009681. Blood Adv. 2023. PMID: 37603349 Free PMC article.
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Charalampous C, et al. Among authors: fonder al. Am J Hematol. 2023 Mar;98(3):413-420. doi: 10.1002/ajh.26806. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588396 Free article.
A simple additive staging system for newly diagnosed multiple myeloma.
Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK. Abdallah NH, et al. Among authors: fonder al. Blood Cancer J. 2022 Jan 31;12(1):21. doi: 10.1038/s41408-022-00611-x. Blood Cancer J. 2022. PMID: 35102148 Free PMC article.
43 results